Anzeige
Mehr »
Donnerstag, 11.06.2026 - Börsentäglich über 12.000 News
Vier Bohrlöcher, vier Treffer - bestätigt sich hier ein neues Uran-System?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PZ3E | ISIN: US18507C1036 | Ticker-Symbol:
NASDAQ
10.06.26 | 21:59
13,720 US-Dollar
-0,22 % -0,030
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
CLEARPOINT NEURO INC Chart 1 Jahr
5-Tage-Chart
CLEARPOINT NEURO INC 5-Tage-Chart

Aktuelle News zur CLEARPOINT NEURO Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiStifel bekräftigt "Buy"-Rating für Clearpoint Neuro dank Neurochirurgie-Plattform1
DiStifel reiterates Clearpoint Neuro stock rating on neurosurgery platform1
27.05.ClearPoint Neuro, Inc.: ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint433Announcement is made after successful proof-of-concept trial in a preclinical model of intravenous delivery of large molecule tracers across the blood-brain barrier guided by prototype systems, including...
► Artikel lesen
21.05.ClearPoint Neuro, Inc. - 8-K, Current Report1
20.05.ClearPoint Neuro, Inc. - S-8, Securities to be offered to employees in employee benefit plans2
14.05.Stifel reiterates Clearpoint Neuro stock Buy rating after Q1 beat1
13.05.ClearPoint Neuro Q1 2026 Earnings Call Transcript1
CLEARPOINT NEURO Aktie jetzt für 0€ handeln
13.05.ClearPoint Neuro, Inc. - 10-Q, Quarterly Report1
13.05.ClearPoint Neuro, Inc. GAAP EPS of -$0.32 misses by $0.05, revenue of $12.13M beats by $0.16M13
13.05.ClearPoint Neuro surgical drill receives CE Mark approval2
13.05.ClearPoint Neuro, Inc.: ClearPoint Neuro Reports First Quarter 2026 Results1.591Record Revenue Achieved Including 25% Organic Growth in Devices and 43% Overall Growth SOLANA BEACH, CA / ACCESS Newswire / May 13, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global...
► Artikel lesen
13.05.Chirurgischer Bohrer von ClearPoint Neuro erhält CE-Zulassung für Europa2
13.05.ClearPoint Neuro, Inc. - 8-K, Current Report2
13.05.ClearPoint Neuro, Inc.: ClearPoint Neuro Announces CE Marking of Velocity Alpha MR High Speed Surgical Drill System, Further Expanding Drug Delivery Ecosystem and Global Footprint290SOLANA BEACH, CA / ACCESS Newswire / May 13, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain...
► Artikel lesen
08.05.Stifel initiates Clearpoint Neuro stock coverage with buy rating1
29.04.ClearPoint Neuro, Inc.: ClearPoint Neuro to Announce First Quarter 2026 Results May 13, 2026808SOLANA BEACH, CA / ACCESS Newswire / April 29, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the...
► Artikel lesen
22.04.ClearPoint Neuro, Inc.: ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint870SOLANA BEACH, CA / ACCESS Newswire / April 22, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) ("Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain...
► Artikel lesen
20.04.ClearPoint Neuro gets Canadian approval for navigation system2
20.04.ClearPoint Neuro, Inc.: ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint343Combined clearance of the navigation and drug delivery technologies enables Canadian neurosurgery centers to leverage the Company's flagship image-guidance workflow and advances ClearPoint Neuro's overall...
► Artikel lesen
18.03.ClearPoint Neuro plunges as FY26 guidance falls below analysts' estimates3
Weiter >>
50 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1